Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer

Journal of the National Cancer Institute

Volumn 98, Issue 17, 2006, Pages 1183-1192

  Buyse, Marc ^a   Loi, Sherene ^b   van't Veer, Laura ^c,f   Viale, Giuseppe ^d   Delorenzi, Mauro ^e   Glas, Annuska M ^f   d'Assignies, Mahasti Saghatchian ^g   Bergh, Jonas ^h   Lidereau, Rosette ⁱ   Ellis, Paul ^j   Harris, Adrian ^k   Bogaerts, Jan ^l   Therasse, Patrick ^l   Floore, Arno ^f   Amakrane, Mohamed ^a   Piette, Fanny ^a   Rutgers, Emiel ^c   Sotiriou, Christos ^b   Cardoso, Fatima ^b   Piccart, Martine J ^b   Decker, N ^b   Straehle, C ^b   more..

^a INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d UNIVERSITY OF MILAN   (Italy)

^e SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^f Agendia NV   (Netherlands)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h KAROLINSKA INSTITUTE   (Sweden)

ⁱ INSERM   (France)

^j GUY S HOSPITAL   (United Kingdom)

^k JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^l EORTC DATA CENTER   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CLINICAL FEATURE; COMPUTER PROGRAM; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EUROPE; FOLLOW UP; GENE IDENTIFICATION; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PATIENT CODING; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; VALIDATION STUDY;

ADULT; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33748693297     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj329     Document Type: Article

References (29)

1. West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A 2001;98:11462-7.
2. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003;100: 10393-8.
3. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumour subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
4. Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, Horng CF, et al. Gene expression predictors of breast cancer outcomes. Lancet 2003;361:1590-6.
5. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
6. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
7. Wang Y, Klijn J, Zhang Y, Sieuwerts A, Look MP, Atkins D, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365:671-9.
8. Weigelt B, Glas AM, Wessels LF, Witteveen AT, Peterse JL, van't Veer LJ. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci U S A 2003;100:15901-5.
9. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003;21:3357-65.
10. Eifel P, Axelson JA, Costa J, Crowley J, Curran WJ Jr, Deshler A, et al. National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001;93:979-89.
11. Simon R, Radmacher MD, Dobbin K, McShane LM. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 2003;95:14-8.
12. Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 2004;4:309-14.
13. Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: A multiple random validation strategy. Lancet 2005;365:488-92.
14. Eden P, Ritz C, Rose C, Ferno M, Peterson C. "Good Old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer 2004;40:1837-41.
15. Todd JH, Dowle C, Williams MR, Elston CW, Ellis IO, Hinton CP, et al. Confirmation of a prognostic index in primary breast cancer. Br J Cancer 1987;56:489-92.
16. Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19:980-91.
17. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002;20:3628-36.
18. Cardoso F. Microarray technology and its effect on breast cancer (re)classification and prediction of outcome. Breast Cancer Res 2003;5: 303-4.
19. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81.
20. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
21. Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005;23:2716-25.
22. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687-717.
23. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000;56:337-44.
24. Kattan MW. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 2003;95:634-5.
25. Simon R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 2005;23:7332-41.
26. Jenssen TK, Hovig E. Gene-expression profiling in breast cancer. Lancet 2005;365:634-5.
27. Foekens JA, Atkins D, Zhang Y, Sweep FC, Harbeck N, Paradiso A, et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 2006;24:1665-71.
28. Ein-Dor L, Kela I, Getz G, Givol D, Domany E. Outcome signature genes in breast cancer: Is there a unique set? Bioinformatics 2004;21:171-8.
29. Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison J, et al. Prospective evaluation of a gene signature as a new prognostic tool in early-stage breast cancer. Nat Clin Pract Oncol. In press 2006.